Table 1.

Immunoconjugates and targeted therapies for HCL

Immunoconjugates and targeted therapies for HCL

rIT indicates recombinant immunotoxin; TKI, thymidine kinase inhibitor; and NHL, non-Hodgkin lymphoma.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal